Hengrui Medicine surges 10% as Q3 profit jumps 89%

Hengrui Medicine (1276.HK) surged 9.57% in Hong Kong trading to HK$49.000, spiking more than 5% within five minutes at one point during the session.

Third-quarter net profit soared 89% year on year to RMB 2.458 billion, far exceeding market expectations. Revenue climbed 20.55% to RMB 8.95 billion, driven by robust innovative drug sales and a 31% increase in licensing income that included a major deal with Novo Nordisk.

For the first nine months, net profit attributable to shareholders rose 20.38% from a year earlier.

Source: HK Stock Market Update The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.